Valley National Advisers’s BioCryst Pharmaceuticals BCRX Stock Holding History

Valley National Advisers’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$100	Buy	+10	New	+$90	﹤0.01%	1030

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

IMC Chicago Chicago, Illinois $419B AUM 72.04% 1-Year Est. Return

OAM

OP Asset Management Helsinki $9.38B AUM 42.35% 1-Year Est. Return

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Valley National Advisers's BCRX Position: Q2 2026 in Review

Valley National Advisers opened a new position in BioCryst Pharmaceuticals (BCRX) in Q2 2026: 10 shares worth $100. The stake represents ﹤0.01% of the portfolio and ranks #1030 among its holdings.

115 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Valley National Advisers held 10 shares of BioCryst Pharmaceuticals worth $100 as of Q2 2026.
BioCryst Pharmaceuticals was a new Valley National Advisers position in Q2 2026.
BioCryst Pharmaceuticals made up ﹤0.01% of Valley National Advisers's portfolio in Q2 2026, its #1030 holding.
115 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Valley National Advisers's 13F filing for Q2 2026, filed 29 Jul 2026.